214 related articles for article (PubMed ID: 36162609)
1. Advances in in-vitro bioequivalence testing methods for complex ophthalmic generic products.
Renukuntla J; Palakurthi SS; Bolla PK; Clark BA; Boddu SHS; Manda P; Sockwell S; Charbe NB; Palakurthi S
Int J Pharm; 2022 Nov; 627():122209. PubMed ID: 36162609
[TBL] [Abstract][Full Text] [Related]
2. Clinical, Pharmacokinetic, and In Vitro Studies to Support Bioequivalence of Ophthalmic Drug Products.
Choi SH; Lionberger RA
AAPS J; 2016 Jul; 18(4):1032-8. PubMed ID: 27184578
[TBL] [Abstract][Full Text] [Related]
3. Classification of torasemide based on the Biopharmaceutics Classification System and evaluation of the FDA biowaiver provision for generic products of CLASS I drugs.
Khan MZ; Rausl D; Radosević S; Filić D; Danilovski A; Dumić M; Knezević Z
J Pharm Pharmacol; 2006 Nov; 58(11):1475-82. PubMed ID: 17132210
[TBL] [Abstract][Full Text] [Related]
4. Drilling down the bioequivalence assessment of topical antifungal products: Microstructure and release.
Miranda M; Cardoso C; Pais AACC; Brown M; Vitorino C
Eur J Pharm Biopharm; 2023 Apr; 185():94-106. PubMed ID: 36806630
[TBL] [Abstract][Full Text] [Related]
5. Pharmaceutical equivalence by design for generic drugs: modified-release products.
Raw AS; Lionberger R; Yu LX
Pharm Res; 2011 Jul; 28(7):1445-53. PubMed ID: 21387150
[TBL] [Abstract][Full Text] [Related]
6. Landscape Analysis of Generic Availability for Oncologic Drugs.
Kumar V; Wang F; Hu M; Kluetz P; Zhao L
Ther Innov Regul Sci; 2023 Nov; 57(6):1279-1286. PubMed ID: 37561261
[TBL] [Abstract][Full Text] [Related]
7. Development of performance matrix for generic product equivalence of acyclovir topical creams.
Krishnaiah YS; Xu X; Rahman Z; Yang Y; Katragadda U; Lionberger R; Peters JR; Uhl K; Khan MA
Int J Pharm; 2014 Nov; 475(1-2):110-22. PubMed ID: 25089511
[TBL] [Abstract][Full Text] [Related]
8. Bioequivalence of topical generic products. Part 2. Paving the way to a tailored regulatory system.
Miranda M; Sousa JJ; Veiga F; Cardoso C; Vitorino C
Eur J Pharm Sci; 2018 Sep; 122():264-272. PubMed ID: 29981406
[TBL] [Abstract][Full Text] [Related]
9. Current Regulation for Bioequivalence Evaluations of Generic Ophthalmic Dosage Forms in Japan.
Myoenzono A; Kuribayashi R; Yamaguchi T; Ogawa T; Takagi K
Eur J Drug Metab Pharmacokinet; 2020 Dec; 45(6):697-702. PubMed ID: 32930951
[TBL] [Abstract][Full Text] [Related]
10. Modified Regulatory Pathways to Approve Generic Drugs in the US and a Systematic Review of Their Outcomes.
Kesselheim AS; Polinski JM; Fulchino LA; Isaman DL; Gagne JJ
Drugs; 2015 Apr; 75(6):633-50. PubMed ID: 25822610
[TBL] [Abstract][Full Text] [Related]
11. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
[TBL] [Abstract][Full Text] [Related]
12. A New Level A Type IVIVC for the Rational Design of Clinical Trials Toward Regulatory Approval of Generic Polymeric Long-Acting Injectables.
Somayaji MR; Das D; Przekwas A
Clin Pharmacokinet; 2016 Oct; 55(10):1179-1190. PubMed ID: 27349905
[TBL] [Abstract][Full Text] [Related]
13. Product Quality Research for Developing and Assessing Regulatory Submissions for Generic Cyclosporine Ophthalmic Emulsions.
Belenos A; Wood EL; Hu M; Kozak D; Xu X; Fisher AC
AAPS J; 2023 Jan; 25(1):20. PubMed ID: 36702976
[TBL] [Abstract][Full Text] [Related]
14. Bioequivalence Common Deficiencies in Generic Products Submitted for Registration to the South African Health Products Regulatory Authority (SAHPRA).
Moeti L; Litedu M; Joubert J
Ther Innov Regul Sci; 2022 Sep; 56(5):822-838. PubMed ID: 35896784
[TBL] [Abstract][Full Text] [Related]
15. In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies.
Kollipara S; Ahmed T; Bhattiprolu AK; Chachad S
Biopharm Drug Dispos; 2021 Jul; 42(7):297-318. PubMed ID: 34019712
[TBL] [Abstract][Full Text] [Related]
16. Generic development of topical dermatologic products: formulation development, process development, and testing of topical dermatologic products.
Chang RK; Raw A; Lionberger R; Yu L
AAPS J; 2013 Jan; 15(1):41-52. PubMed ID: 23054971
[TBL] [Abstract][Full Text] [Related]
17. The role of predictive biopharmaceutical modeling and simulation in drug development and regulatory evaluation.
Jiang W; Kim S; Zhang X; Lionberger RA; Davit BM; Conner DP; Yu LX
Int J Pharm; 2011 Oct; 418(2):151-60. PubMed ID: 21803144
[TBL] [Abstract][Full Text] [Related]
18. Dissolution testing for generic drugs: an FDA perspective.
Anand O; Yu LX; Conner DP; Davit BM
AAPS J; 2011 Sep; 13(3):328-35. PubMed ID: 21479700
[TBL] [Abstract][Full Text] [Related]
19. Scientific Considerations for the Review and Approval of First Generic Mometasone Furoate Nasal Suspension Spray in the United States from the Bioequivalence Perspective.
Liu Q; Absar M; Saluja B; Guo C; Chowdhury B; Lionberger R; Conner DP; Li BV
AAPS J; 2019 Jan; 21(2):14. PubMed ID: 30617594
[TBL] [Abstract][Full Text] [Related]
20. Modernization and Strengthening of Bioequivalence Guidelines in Japan.
Kuribayashi R; Yamaguchi T; Takagi K
Clin Pharmacokinet; 2021 Feb; 60(2):145-151. PubMed ID: 33247363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
